Regeneron Secures Approval for First Targeted Bullous Pemphigoid Therapy in Japan

Regeneron Pharmaceuticals has secured Japan's first targeted bullous pemphigoid therapy approval for Dupixent, making it the first targeted treatment for the condition in Japan and adding a seventh approved indication for the drug. This decision reinforces Dupixent's immunology franchise story, but the company's core thesis remains rooted in turning immunology and ophthalmology innovation into durable cash flows and diversifying beyond EYLEA. The approval highlights Dupixent's potential as a counterweight to EYLEA pressure and a key catalyst for ongoing regulatory decisions and uptake trends.